<PAGE> 1
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON OCTOBER 9, 1997
REGISTRATION NO. 333-
================================================================================
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
------------------------
FORM S-1
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
------------------------
COULTER PHARMACEUTICAL, INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
<TABLE>
<S> <C> <C>
DELAWARE 2834 94-3219075
(STATE OR OTHER JURISDICTION OF (PRIMARY STANDARD INDUSTRIAL (I.R.S. EMPLOYER
INCORPORATION OR ORGANIZATION) CLASSIFICATION CODE NUMBER) IDENTIFICATION NUMBER)
</TABLE>
------------------------
550 CALIFORNIA AVENUE, SUITE 200
PALO ALTO, CALIFORNIA 94306-1440
(650) 842-7300
(ADDRESS, INCLUDING ZIP CODE, AND TELEPHONE NUMBER,
INCLUDING AREA CODE, OF REGISTRANT'S PRINCIPAL EXECUTIVE OFFICES)
------------------------
MICHAEL F. BIGHAM
PRESIDENT AND CHIEF EXECUTIVE OFFICER
COULTER PHARMACEUTICAL, INC.
550 CALIFORNIA AVENUE, SUITE 200
PALO ALTO, CALIFORNIA 94306-1440
(650) 842-7300
(NAME, ADDRESS AND TELEPHONE NUMBER OF AGENT FOR SERVICE)
------------------------
COPIES TO:
<TABLE>
<S> <C>
JAMES C. KITCH, ESQ. ALAN K. AUSTIN, ESQ.
JOHN A. DADO, ESQ. ELIZABETH R. FLINT, ESQ.
COOLEY GODWARD LLP WILSON SONSINI GOODRICH & ROSATI
FIVE PALO ALTO SQUARE PROFESSIONAL CORPORATION
3000 EL CAMINO REAL 650 PAGE MILL ROAD
PALO ALTO, CALIFORNIA 94306 PALO ALTO, CALIFORNIA 94304
</TABLE>
------------------------
APPROXIMATE DATE OF PROPOSED SALE TO THE PUBLIC: As soon as practicable
after the effective date of this Registration Statement.
------------------------
If this Form is filed to register additional securities for an offering
pursuant to Rule 462(b) under the Securities Act, please check the following box
and list the Securities Act registration statement number of the earlier
effective registration statement for the same offering. [X] 333-36607
------------------------
CALCULATION OF REGISTRATION FEE
================================================================================
<TABLE>
<CAPTION>
TITLE OF SECURITIES AMOUNT TO BE PROPOSED MAXIMUM OFFERING PROPOSED MAXIMUM AGGREGATE AMOUNT OF
TO BE REGISTERED REGISTERED(1) PRICE PER SHARE OFFERING PRICE REGISTRATION FEE
- ------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C>
Common Stock,
$0.001 par value............ 402,500 $15.50 $6,238,750 $1,891
========================================================================================================================
</TABLE>
(1) Includes 52,500 shares of Common Stock issuable upon exercise of the
Underwriters' over-allotment option.
================================================================================
EXPLANATORY NOTE
This registration statement is being filed pursuant to Rule 462(b) and
General Instruction V of Form S-1. Incorporated by reference herein is, in its
entirety, the Registration Statement on Form S-1 (File No. 333-36607) of
Coulter Pharmaceutical, Inc., which was declared effective by the Securities
and Exchange Commission on October 9, 1997.
<PAGE> 2
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the Registrant
has caused this Registration Statement to be signed on its behalf by the
undersigned, thereunto duly authorized, in the City of Palo Alto, County of
Santa Clara, State of California, on the 9th day of October, 1997.
COULTER PHARMACEUTICAL, INC.
By: /s/ MICHAEL F. BIGHAM
------------------------------------
Michael F. Bigham
President, Chief Executive Officer
and
Director (Principal Executive
Officer)
<TABLE>
<CAPTION>
SIGNATURE TITLE DATE
- ------------------------------------- ------------------------------------ ------------------
<C> <S> <C>
/s/ MICHAEL F. BIGHAM President, Chief Executive Officer October 9 , 1997
- ------------------------------------- and Director (Principal Executive
Michael F. Bigham Officer)
/s/ WILLIAM G. HARRIS* Vice President and Chief Financial October 9, 1997
- ------------------------------------- Officer (Principal Financial and
William G. Harris Accounting Officer)
/s/ BRIAN G. ATWOOD* Director October 9, 1997
- -------------------------------------
Brian G. Atwood
/s/ DONALD L. LUCAS* Director October 9, 1997
- -------------------------------------
Donald L. Lucas
Director October 9, 1997
- -------------------------------------
Robert Momsen
/s/ ARNOLD ORONSKY* Director October 9, 1997
- -------------------------------------
Arnold Oronsky
/s/ SUE VAN* Director October 9, 1997
- -------------------------------------
Sue Van
Director October 9, 1997
- -------------------------------------
George J. Sella, Jr.
/s/ JOSEPH R. COULTER, III* Director October 9, 1997
- -------------------------------------
Joseph R. Coulter, III
*By: /s/ MICHAEL F. BIGHAM
- -------------------------------------
Michael F. Bigham
Attorney in Fact
</TABLE>
<PAGE> 3
EXHIBIT INDEX
<TABLE>
<CAPTION>
EXHIBIT EXHIBIT
FOOTNOTE NUMBER DESCRIPTION OF DOCUMENT
- --------- ------ ---------------------------------------------------------------------
<C> <C> <S>
(5) 5.1 Opinion of Cooley Godward LLP.
23.1 Consent of Ernst & Young LLP.
23.2 Consent of Cooley Godward LLP. Reference is made to Exhibit 5.1.
</TABLE>
<PAGE> 1
[COOLEY GODWARD LETTERHEAD]
October 9, 1997
Coulter Pharmaceutical, Inc.
550 California Avenue, Suite 200
Palo Alto, California 94306-1440
Ladies and Gentlemen:
You have requested our opinion with respect to certain matters in
connection with the filing on the date hereof by Coulter Pharmaceutical, Inc.
(the "Company") of a post effective amendment pursuant to Rule 462(b) to the
Registration Statement on Form S-1 on September 29, 1997, as amended (the
"Registration Statement") with the Securities and Exchange Commission covering
the offering of up to an additional Four Hundred Two Thousand Five Hundred
(402,500) shares of the Company's Common Stock, $.001 par value (the "Shares").
In connection with this opinion, we have examined the Registration
Statement and related Prospectus, your Restated Certificate of Incorporation and
Bylaws, as amended, and such other documents, records, certificates, memoranda
and other instruments as we deem necessary as a basis for this opinion. We have
assumed the genuineness and authenticity of all documents submitted to us as
originals, the conformity to originals of all documents submitted to us as
copies thereof, and the due execution and delivery of all documents where due
execution and delivery are a prerequisite to the effectiveness thereof.
On the basis of the foregoing, and in reliance thereon, we are of the
opinion that the Shares, when sold and issued in accordance with the
Registration Statement and related Prospectus, will be validly issued, fully
paid, and nonassessable.
We consent to the filing of this opinion as an exhibit to the Registration
Statement.
Very truly yours,
Cooley Godward LLP
/s/ JAMES C. KITCH
James C. Kitch
<PAGE> 1
EXHIBIT 23.1
CONSENT OF ERNST & YOUNG LLP, INDEPENDENT AUDITORS
We consent to the reference to our firm under the captions "Selected
Consolidated Financial Data" and "Experts" and to the use of our report dated
February 2, 1997 with respect to the consolidated financial statements of
Coulter Pharmaceutical, Inc. and our report dated November 27, 1996 with respect
to the Antibody Therapeutics Business Operations of Coulter Corporation, in the
Registration Statement (Form S-1) and related Prospectus of Coulter
Pharmaceutical, Inc. for the registration of shares of its common stock.
/s/ ERNST & YOUNG LLP
Palo Alto, California
October 9, 1997
